---
schema_version: "secwatch.filing_event.v1"
accession: "0001599298-24-000096"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2024-05-30T23:59:59+00:00"
generated_at: "2026-06-01T07:24:04.416024+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Summit: Ivonescimab beats pembrolizumab in Phase III HARMONi-2 for PD-L1+ NSCLC

## Summary
- Ivonescimab met primary endpoint PFS with statistically significant and clinically meaningful superiority over pembrolizumab.
- Benefit observed across subgroups: PD-L1 low/high, squamous/non-squamous, and high-risk patients.
- First drug to show statistically significant superiority over pembrolizumab in a head-to-head Phase III NSCLC trial.
- Full data set to be presented at upcoming major medical conference; conference call June 3 at 8am ET.
- Summit plans to expand development of ivonescimab into other tumors beyond NSCLC.

## SEC filing metadata
- accession: 0001599298-24-000096
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2024-05-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929824000096/0001599298-24-000096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000159929824000096/smmt-20240530.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599298-24-000096
- JSON: https://secwatch.observer/filing/0001599298-24-000096.json
- Plain text: https://secwatch.observer/filing/0001599298-24-000096.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.